Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı

Deniz Zeynep Telci; Banu Dokuzeylül; M. Erman Or

doi:10.51755/turkvetj.1835180

EN TR

Clinical Use of FGF-23 in Feline Chronic Kidney Disease

Abstract

Fibroblast growth factor-23 (FGF-23) is a hormone synthesized primarily by osteocytes and other bone cells, playing a key role in the regulation of phosphate metabolism. Its main effects include increasing renal phosphate excretion to reduce serum phosphate levels and limiting intestinal phosphate absorption by suppressing 1α-hydroxylase activity and consequently decreasing calcitriol synthesis. In cats with chronic kidney disease (CKD), plasma FGF-23 concentrations have been observed to increase in parallel with the loss of renal function and advancing IRIS stage. When cats with chronic kidney disease are compared, the detection of higher FGF-23 levels in hyperphosphatemic individuals suggests that this hormone may serve as an early biomarker reflecting disturbances in phosphate metabolism. Studies indicate that FGF-23 may be useful not only in the diagnosis of CKD but also in the diagnosis of secondary renal hyperparathyroidism and in monitoring phosphate-restricted therapeutic interventions. This review aims to provide a comprehensive evaluation of the association of FGF-23 with CKD in cats, its pathophysiological role, and its potential applications in veterinary clinical practice.

Keywords

Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı

Abstract

Fibroblast büyüme faktörü-23 (FGF-23), başlıca osteositler olmak üzere kemik hücrelerinden sentezlenen ve fosfat metabolizmasının düzenlenmesinde kilit rol oynayan bir hormondur. Temel etkileri, böbreklerden fosfat atılımını artırarak serum fosfat düzeylerini düşürmek ve 1α-hidroksilaz aktivitesini baskılayarak kalsitriol sentezini azaltmak yoluyla bağırsaktan fosfat emilimini sınırlamaktır. Kronik böbrek hastalığı (KBH) bulunan kedilerde plazma FGF-23 düzeyinin, böbrek fonksiyon kaybı ve IRIS evresinin ilerlemesi ile birlikte yükseldiği gözlemlenmiştir. Kronik böbrek hastalığı bulunan kediler karşılaştırıldığında, hiperfosfatemili olgularda daha yüksek FGF-23 düzeylerinin saptanması, bu hormonun fosfat metabolizmasındaki bozulmayı erken dönemde yansıtan bir biyobelirteç olabileceğini düşündürmektedir. Yapılan araştırmalar FGF-23’ün yalnızca KBH tanısında değil, sekonder renal hiperparatiroidizmin tanısında ve fosfat kısıtlamasına dayalı tedavilerin izlenmesinde de yararlı bir biyobelirteç olabileceğini göstermektedir. Bu derlemede, FGF-23’ün kedilerde KBH ile ilişkisinin, patofizyolojik rolünün ve veteriner pratiğinde kullanım olanaklarının kapsamlı şekilde değerlendirilmesi amaçlanmıştır.

Keywords

References

Barber, P. J., & Elliott, J. (1998). Feline chronic renal failure: Calcium homeostasis in 80 cases diagnosed between 1992 and 1995. Journal of Small Animal Practice, 39(3), 108–116. https://doi.org/10.1111/j.1748-5827.1998.tb03613.x
Brown, C. A., Elliott, J., Schmiedt, C. W., & Brown, S. A. (2016). Chronic kidney disease in aged cats: Clinical features, morphology, and proposed pathogeneses. Veterinary Pathology, 53(2), 309–326. https://doi.org/10.1177/0300985815622975
Chakrabarti, S., Syme, H. M., & Elliott, J. (2012). Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. Journal of Veterinary Internal Medicine, 26(2), 275–281. https://doi.org/10.1111/j.1939-1676.2011.00874.x
De Brito Galvão, J. F., Nagode, L. A., Schenck, P. A., & Chew, D. J. (2013). Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. Journal of Veterinary Emergency and Critical Care, 23(2), 134–162. https://doi.org/10.1111/vec.12036
Elliott, J., & Geddes, R. F. (2022). New concepts in phosphorus homeostasis and its impact on renal health with particular reference to the cat. The Veterinary Journal, 105842. doi: 10.1016/j.tvjl.2022.105842.
Elliott, J., & Tang, P. K. (2025). Fibroblast Growth Factor 23 – A review with particular reference to the physiology and pathophysiology of phosphate homeostasis in the cat. The Veterinary Journal, 106271. https://doi.org/10.1016/j.tvjl.2024.106271
Finch, N. C., Geddes, R. F., Syme, H. M., & Elliott, J. (2013). Fibroblast growth factor-23 concentrations in cats with early nonazotemic chronic kidney disease (CKD) and in healthy geriatric cats. Journal of Veterinary Internal Medicine, 27(2), 227–233. https://doi.org/10.1111/jvim.12036
Geddes, R. F., Elliott, J., & Syme, H. M. (2013b). The effect of feeding a renal diet on plasma fibroblast growth factor 23 concentrations in cats with stable azotemic chronic kidney disease. Journal of Veterinary Internal Medicine, 27(6), 1354–1361. https://doi.org/10.1111/jvim.12187

Geddes, R. F., Elliott, J., & Syme, H. M. (2015). Relationship between plasma fibroblast growth factor-23 concentration and survival time in cats with chronic kidney disease. Journal of Veterinary Internal Medicine, 29(6), 1494–1501. https://doi.org/10.1111/jvim.13625
Geddes, R. F., Finch, N. C., Elliott, J., & Syme, H. M. (2013a). Fibroblast growth factor 23 in feline chronic kidney disease. Journal of Veterinary Internal Medicine, 27(2), 234–241. https://doi.org/10.1111/jvim.12044
Geddes, R. F., van den Broek, D. H. N., Chang, Y. M., Biourge, V., Elliott, J., & Jepson, R. E. (2021). The effect of attenuating dietary phosphate restriction on blood ionized calcium concentrations in cats with chronic kidney disease and ionized hypercalcemia. Journal of Veterinary Internal Medicine, 35(2), 997–1007. https://doi.org/10.1111/jvim.16050
Gutiérrez, O. M. (2010). Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the “trade-off” hypothesis. Clinical Journal of the American Society of Nephrology, 5(9), 1710–1716. https://doi.org/10.2215/CJN.02640310
Hall, J. A., Yerramilli, M., Obare, E., Yerramilli, M., & Jewell, D. E. (2014). Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. Journal of Veterinary Internal Medicine, 28(6), 1676–1683. https://doi.org/10.1111/jvim.12445
Hardcastle, M. R., & Dittmer, K. E. (2015). Fibroblast growth factor 23: A new dimension to diseases of calcium-phosphorus metabolism. Veterinary Pathology, 52(5), 770–784. https://doi.org/10.1177/0300985815586222
International Renal Interest Society (IRIS). (2023a). IRIS staging of chronic kidney disease (modified 2023). Available at: https://www.iris-kidney.com
International Renal Interest Society (IRIS). (2023b). A review of the role of fibroblast growth factor 23 in phosphate homeostasis and the pathophysiology of mineral bone disorder associated with chronic kidney disease. https://www.iris-kidney.com/new-page-4
Laflamme, D., Backus, R., Brown, S., Butterwick, R., Czarnecki-Maulden, G., Elliott, J., … & Polzin, D. (2020). A review of phosphorus homeostasis and the impact of different types and amounts of dietary phosphate on metabolism and renal health in cats. Journal of Veterinary Internal Medicine, 34(6), 2187–2196. https://doi.org/10.1111/jvim.15961
Lapsina, S., von Luckner, J., Nagler, N., Müller, S. F., Müller, E., & Schäfer, I. (2024). Establishing a reference interval for fibroblast growth factor (FGF)-23 in cats. Animals, 14(11), 1670. https://doi.org/10.3390/ani14111670
Lin, J., Lin, L., Chen, S., Yu, L., Chen, S., & Xia, Z. (2021). Serum fibroblast growth factor 23: Associations with hyperphosphatemia and clinical staging of feline chronic kidney disease. Journal of Veterinary Diagnostic Investigation, 33(2), 288–293. https://doi.org/10.1177/1040638720985563
Maden, M., Ider, M., Or, M. E., Dokuzeylül, B., Gülersoy, E., Kılıçkaya, M. C., … & Naseri, A. (2024). The clinical efficacy of cGMP-specific sildenafil on mitochondrial biogenesis induction and renal damage in cats with acute on chronic kidney disease. BMC Veterinary Research, 20, 499. https://doi.org/10.1186/s12917-024-04345-9
Marino, C. L., Lascelles, B. D. X., Vaden, S. L., Gruen, M. E., & Marks, S. L. (2014). Prevalence and classification of chronic kidney disease in cats randomly selected from four age groups and in cats recruited for degenerative joint disease studies. Journal of Feline Medicine and Surgery, 16(6), 465–472. https://doi.org/10.1177/1098612X13511446
Miyakawa, H., Hsu, H. H., Ogawa, M., Akabane, R., Miyagawa, Y., & Takemura, N. (2021). Serum fibroblast growth factor-23 concentrations in young and mature adult cats with chronic kidney disease. Journal of Feline Medicine and Surgery, 1098612X211039192. https://doi.org/10.1177/1098612X211039192
Miyakawa, H., Hsu, H. H., Ogawa, M., Akabane, R., Miyagawa, Y., & Takemura, N. (2022). Association between serum fibroblast growth factor-23 concentrations and blood calcium levels in chronic kidney disease cats with upper urolithiasis. Journal of Feline Medicine and Surgery, 1098612X221075278. https://doi.org/10.1177/1098612X221075278
Polzin, D. J. (2013). Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. Journal of Veterinary Emergency and Critical Care, 23(2), 205–215. https://doi.org/10.1111/vec.12034
Sargent, H. J., Jepson, R. E., Chang, Y. M., Biourge, V. C., Bijsmans, E. S., & Elliott, J. (2019). Fibroblast growth factor 23 and symmetric dimethylarginine concentrations in geriatric cats. Journal of Veterinary Internal Medicine, 33(6), 2657–2664. https://doi.org/10.1111/jvim.15590
Sargent, H. J., Elliott, J., & Jepson, R. E. (2021). The new age of renal biomarkers: does SDMA solve all of our problems?. Journal of Small Animal Practice, 62(2), 71-81. https://doi.org/10.1111/jsap.13236
Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., … & Yamashita, T. (2005). Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. American Journal of Physiology-Renal Physiology, 289(5), F1088–F1095. https://doi.org/10.1152/ajprenal.00474.2004
Slatopolsky, E. (2011). The intact nephron hypothesis: The concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney International, 79(Suppl. 121), S3–S8. https://doi.org/10.1038/ki.2011.23
Summers, S., Geddes, R. F., Chang, Y.-M., Syme, H. M., & Elliott, J. (2024). Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: A scoping review. Journal of Feline Medicine and Surgery, 26(4), 1234–1248. https://doi.org/10.1177/1098612X241234984
Summers, S., Geddes, R. F., Chang, Y.-M., Syme, H. M., & Elliott, J. (2025). Weekly biological variation of serum biochemistry analytes and fibroblast growth factor-23 in healthy and chronic kidney disease cats. Journal of Small Animal Practice, 66(2), 123–132. https://doi.org/10.1111/jsap.13752
Syme, H. M., Markwell, P. J., Pfeiffer, D., & Elliott, J. (2006). Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. Journal of Veterinary Internal Medicine, 20(3), 528–535. https://doi.org/10.1111/j.1939-1676.2006.tb02892.x
Vervloet, M. G. (2022). Shedding light on the complex regulation of FGF23. Metabolites, 12(5), 401. https://doi.org/10.3390/metabo12050401
Von Hendy-Willson, V. E., & Pressler, B. M. (2011). An overview of glomerular filtration rate testing in dogs and cats. The Veterinary Journal, 188(2), 156–165. https://doi.org/10.1016/j.tvjl.2010.05.006

Details

Primary Language

Turkish

Subjects

Veterinary Sciences (Other)

Journal Section

Review

Authors

Deniz Zeynep Telci ^*
0000-0001-6825-2093
Türkiye

Banu Dokuzeylül
0000-0003-3086-4726
Türkiye

M. Erman Or
0000-0002-8764-1956
Türkiye

Publication Date

June 30, 2026

Submission Date

December 3, 2025

Acceptance Date

May 13, 2026

Published in Issue

Year 2026 Volume: 8 Number: 1

DOI

https://doi.org/10.51755/turkvetj.1835180

IZ

https://izlik.org/JA92WC83BE

Cite

RIS / Bibtex

APA

Telci, D. Z., Dokuzeylül, B., & Or, M. E. (2026). Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı. Turkish Veterinary Journal, 8(1), 20-25. https://doi.org/10.51755/turkvetj.1835180

AMA

1.Telci DZ, Dokuzeylül B, Or ME. Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı. Turk Vet J. 2026;8(1):20-25. doi:10.51755/turkvetj.1835180

Chicago

Telci, Deniz Zeynep, Banu Dokuzeylül, and M. Erman Or. 2026. “Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı”. Turkish Veterinary Journal 8 (1): 20-25. https://doi.org/10.51755/turkvetj.1835180.

EndNote

Telci DZ, Dokuzeylül B, Or ME (June 1, 2026) Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı. Turkish Veterinary Journal 8 1 20–25.

IEEE

[1]D. Z. Telci, B. Dokuzeylül, and M. E. Or, “Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı”, Turk Vet J, vol. 8, no. 1, pp. 20–25, June 2026, doi: 10.51755/turkvetj.1835180.

ISNAD

Telci, Deniz Zeynep - Dokuzeylül, Banu - Or, M. Erman. “Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı”. Turkish Veterinary Journal 8/1 (June 1, 2026): 20-25. https://doi.org/10.51755/turkvetj.1835180.

JAMA

1.Telci DZ, Dokuzeylül B, Or ME. Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı. Turk Vet J. 2026;8:20–25.

MLA

Telci, Deniz Zeynep, et al. “Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı”. Turkish Veterinary Journal, vol. 8, no. 1, June 2026, pp. 20-25, doi:10.51755/turkvetj.1835180.

Vancouver

1.Deniz Zeynep Telci, Banu Dokuzeylül, M. Erman Or. Kedilerde Kronik Böbrek Hastalığında FGF-23’ün Klinik Kullanımı. Turk Vet J. 2026 Jun. 1;8(1):20-5. doi:10.51755/turkvetj.1835180